The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data


Variant: NM_000132.4(F8):c.6089G>A (p.Ser2030Asn)

CA10567911

439683 (ClinVar)

Gene: F8
Condition: hemophilia A
Inheritance Mode: X-linked inheritance
UUID: 02958bef-ef7e-40eb-a41a-a45bb873a1b0
Approved on: 2025-03-10
Published on: 2025-03-10

HGVS expressions

NM_000132.4:c.6089G>A
NM_000132.4(F8):c.6089G>A (p.Ser2030Asn)
NC_000023.11:g.154902077C>T
CM000685.2:g.154902077C>T
NC_000023.10:g.154130352C>T
CM000685.1:g.154130352C>T
NC_000023.9:g.153783546C>T
NG_011403.1:g.125647G>A
NG_011403.2:g.125647G>A
ENST00000360256.9:c.6089G>A
ENST00000360256.8:c.6089G>A
NM_000132.3:c.6089G>A
More

Pathogenic

Met criteria codes 3
PS4_Very Strong PS3 PP4
Not Met criteria codes 2
PP3 PM2

Evidence Links 1

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Coagulation Factor Deficiency Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for F8 Version 1.0.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Coagulation Factor Deficiency VCEP
c.6089G>A (p.Ser2030Asn) is a pathogenic with no predicted deleterious effect due to the REVEL score of .573, just below meeting criteria for PP3 (>=.6) It also has a SpliceAI score of .05, not meeting criteria for PP3 (>=.5). The c.6089G>A (p.Ser2030Asn) variant is present in gnomAD v2 with a MAF of 0.00002729 (5/81740) for the European (non-Finnish) population. There are 3 hemizygotes and 2 homozygotes. It was absent from gnomAD v3 meeting PM2_supporting. There are 13 probands with this variant reported in MLoF with mild hemophilia, meeting PP4. There were 24 probands reported but only 20 met criteria making it PS4_very-strong. Cells were measured by ELISA and chromogenic assays showing a deleterious effect on rFVIII expression, as shown by the reduced but appreciable levels of rFVIII protein (25%–70% of wild-type) and activity (10%–50%), meeting PS3_Moderate. This variant is classified as Pathogenic for Hemophilia A based on the ACMG/AMP criteria applied, as specified by the ClinGen Coagulation Factor Deficiency Variant Curation Expert Panel for F8 (version 1.0.0, released 10/5/2023): PS4_Very-strong, PP4, PS3
Met criteria codes
PS4_Very Strong
24 probands reported, 20 counted
PS3
Measured by ELISA and chromogenic assays, the variant was associated with 27% factor VIII activity level.

PP4
1 patient with mild hemophilia A reported in MLOF.
Not Met criteria codes
PP3
For the c.6089G>A (p.Ser2030Asn) variant, the REVEL score is .573, not meeting criteria for PP3 (>=.6) It also has a SpliceAI score of .05, not meeting criteria for PP3 (>=.5).
PM2
The c.6089G>A (p.Ser2030Asn) variant is present in gnomAD v2 with a MAF of 0.00002729 (5/81740) for the European (non-Finnish) population. There are 3 hemizygotes and 2 homozygotes. It was absent from gnomAD v3.
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.